73 related articles for article (PubMed ID: 18639600)
41. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
[TBL] [Abstract][Full Text] [Related]
42. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
43. The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis.
Derrick SC; Perera LP; Dheenadhayalan V; Yang A; Kolibab K; Morris SL
Vaccine; 2008 Nov; 26(48):6092-8. PubMed ID: 18809446
[TBL] [Abstract][Full Text] [Related]
44. Pancreas carcinoma antigen fused to invariant chain elicits T-cell response and tumor growth inhibition.
Nagaraj S; Neumann J; Winzen B; Frank S; Ziske C; Sievers E; Koch N; Schmidt-Wolf IG
Pancreas; 2008 Oct; 37(3):321-7. PubMed ID: 18815556
[TBL] [Abstract][Full Text] [Related]
45. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O
Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160
[TBL] [Abstract][Full Text] [Related]
46. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
47. Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma.
Kang MH; Harutyunyan N; Hall CP; Papa RA; Lock RB
Br J Haematol; 2009 May; 145(3):389-93. PubMed ID: 19298590
[TBL] [Abstract][Full Text] [Related]
48. Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.
Bergmann-Leitner ES; Leitner WW; Duncan EH; Savranskaya T; Angov E
Vaccine; 2009 Sep; 27(41):5700-8. PubMed ID: 19576940
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene.
Changhong S; Hai Z; Limei W; Jiaze A; Li X; Tingfen Z; Zhikai X; Yong Z
Tuberculosis (Edinb); 2009 Jan; 89(1):54-61. PubMed ID: 19056317
[TBL] [Abstract][Full Text] [Related]
50. Glycopeptide vaccine on DNA-histone carrier and its impact on Z-potential of effector cells during experimental treatment of lymphoblastic leukemia.
Janisch YV; Artamonova AB; Shlyakhovenko VA
Exp Oncol; 2013 Sep; 35(3):198-201. PubMed ID: 24084458
[TBL] [Abstract][Full Text] [Related]
51. Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
Jo S; Lee JH; Mattei JJ; Barrett DM; van den Elzen P; Grupp SA; Reid GSD; Seif AE
Leukemia; 2018 Feb; 32(2):539-542. PubMed ID: 28924244
[No Abstract] [Full Text] [Related]
52. The dendritic cell: the piano player in orchestrating the immune response in leukemia.
van de Loosdrecht AA
Leuk Lymphoma; 2007 Feb; 48(2):217-8. PubMed ID: 17325876
[No Abstract] [Full Text] [Related]
53. Toll-like receptors in immunity and inflammatory diseases: Past, present, and future.
Vijay K
Int Immunopharmacol; 2018 Jun; 59():391-412. PubMed ID: 29730580
[TBL] [Abstract][Full Text] [Related]
54. Advances in Non-Viral DNA Vectors for Gene Therapy.
Hardee CL; Arévalo-Soliz LM; Hornstein BD; Zechiedrich L
Genes (Basel); 2017 Feb; 8(2):. PubMed ID: 28208635
[TBL] [Abstract][Full Text] [Related]
55. Trial Watch: Toll-like receptor agonists in oncological indications.
Aranda F; Vacchelli E; Obrist F; Eggermont A; Galon J; Sautès-Fridman C; Cremer I; Henrik Ter Meulen J; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014; 3():e29179. PubMed ID: 25083332
[TBL] [Abstract][Full Text] [Related]
56. Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity.
Ridnour LA; Cheng RY; Switzer CH; Heinecke JL; Ambs S; Glynn S; Young HA; Trinchieri G; Wink DA
Clin Cancer Res; 2013 Mar; 19(6):1340-6. PubMed ID: 23271799
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signaling.
Gosu V; Basith S; Kwon OP; Choi S
Molecules; 2012 Nov; 17(11):13503-29. PubMed ID: 23151919
[TBL] [Abstract][Full Text] [Related]
58. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.
Galluzzi L; Vacchelli E; Eggermont A; Fridman WH; Galon J; Sautès-Fridman C; Tartour E; Zitvogel L; Kroemer G
Oncoimmunology; 2012 Aug; 1(5):699-716. PubMed ID: 22934262
[TBL] [Abstract][Full Text] [Related]
59. Targeting pattern recognition receptors in cancer immunotherapy.
Goutagny N; Estornes Y; Hasan U; Lebecque S; Caux C
Target Oncol; 2012 Mar; 7(1):29-54. PubMed ID: 22399234
[TBL] [Abstract][Full Text] [Related]
60. Targeting Toll-like receptors: emerging therapeutics?
Hennessy EJ; Parker AE; O'Neill LA
Nat Rev Drug Discov; 2010 Apr; 9(4):293-307. PubMed ID: 20380038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
